摘要
目的 评价99Tc 亚甲基二膦酸盐 (MDP ,“云克”)治疗Graves眼病 (GO)的疗效。方法 “云克”组静脉注射“云克”AB针每日 1套 (每套 5mg) ,2 0d为 1个疗程 ,1～ 3个疗程 ;对照组泼尼松30～ 5 0mg隔日 1次 ,口服 3个月。治疗前观察GO活动指标 ,以后每月 1次 ,共 3个月。进行疗效和副作用评判。结果 “云克”治疗组抑制GO活动性的有效率为 96 % (2 5 2 6例 ) ,泼尼松治疗组为 6 0 %(9 15例 ) ,两组间差异有显著性 (χ2 =36 0 9.5 ,P <0 .0 0 1)。结论 “云克”治疗GO优于泼尼松 。
Objective To inspect the therapeutic effectiveness of 99 Tc MDP (commodity name: 'Yunke' and it is composed of A, B injections as one set) for Graves' ophthalmopathy (GO) comparing with prednisone. Methods The group of 'Yunke' intravenous injection, one set of A+B per day(5 mg/set), the group of prednisone, oral application of prednisone, 30～50 mg every other day for three months. GO parameters were tested and recorded before treatment, and at every month after treatment for three months. Results A remarkable curb of GO activity was observed in 25/26(96%) cases in 'Yunke' group and 9/15(60%) cases in prednisone group. There was significant difference in the degree of improvement between two groups (χ 2=3 609.5, P< 0.001). The treatment response to 'Yunke' was better than that to prednisone, no evident side effects were found. Conclusion The therapeutic efficacy of 'Yunke' on GO is obvious, but the long term effect deserves more investigation.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2002年第4期204-205,共2页
Chinese Journal of Nuclear Medicine
